SHAANXI PANLONG PHARMACEUTICAL GROUP LIMITED BY SHARE LTD

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd

002864

CNE1000032C9

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
29.16 ^CNY	+0.17%		+3.00%	-24.24%

Apr. 25	Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 25	Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd authorizes a Buyback Plan.

March 12, 2024

The Board of Directors of Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd has authorized a buyback plan on March 13, 2024.

Latest news about Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25	CI
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Tranche Update on Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd's Equity Buyback Plan announced on March 14, 2024.	Apr. 02	CI
Panlong Pharmaceutical Plans 20 Million Yuan Share Buyback	Mar. 14	MT
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd announces an Equity Buyback for CNY 20 million worth of its shares.	Mar. 13	CI
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd authorizes a Buyback Plan.	Mar. 12	CI
Panlong Pharmaceutical Gets Sanitary License	Jan. 15	MT
Panlong Pharmaceutical Gets Certificate for Shaanxi Good Trademark	Dec. 27	MT
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-29	CI
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd announced that it has received CNY 301.999975 million in funding	23-10-08	CI
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-23	CI
Panlong Pharma Completes Registration of New Medical Clinic	23-06-09	MT
Chinese Shares Retreat; Panlong Pharma Falls 7% on 302 Million Yuan Share Sale	23-05-09	MT
Shaanxi Panlong Pharma Selling 302 Million Yuan Shares to Fund New Projects	23-05-09	MT
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-06	CI
Panlong Pharma Gets US Patent for Coronavirus Protease Inhibitor	23-04-04	MT
Shaanxi Panlong Pharma Raising 302 Million Yuan From Share Sale	23-02-27	MT
Shaanxi Panlong Pharma to Pay Interest on 276 Million Yuan Bonds	23-02-24	MT
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd announced that it expects to receive CNY 302 million in funding	22-10-27	CI
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Shaanxi Panlong Pharmaceutical Group Limited by Share Ltd Approves Management Appointments	22-09-13	CI
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-24	CI
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-25	CI
Panlong Pharmaceutical Sells $44 Million RMB Convertible Bonds	22-03-01	MT

Chart Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd

Duration

Period

Chart Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd

More charts

SHAANXI PANLONG PHARMACEUTICAL GROUP LIMITED BY SHARE LTD is a China-based company principally engaged in the research, development, manufacture and sales of Chinese patent drugs. The Company's main product is Panlong Qipian, which is for the treatment of orthopedic rheumatism diseases. The Company also provides other Chinese patent drugs for the treatment of hepatobiliary, cardiovascular and cerebrovascular, gynecological and anti-tumor diseases. The Company is also involved in the production and sales of Chinese herbal pieces, as well as the medical commercial distribution business. The Company distributes its products within domestic market.

Sector

Pharmaceuticals

Calendar

2024-05-21 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

29.16 CNY

Average target price

41.72 CNY

Spread / Average Target

+43.07%

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SHAANXI PANLONG PHARMACEUTICAL GROUP LIMITED BY SHARE LTD	-24.24%	424M
ELI LILLY AND COMPANY	+26.08%	662B
NOVO NORDISK A/S	+21.85%	546B
JOHNSON & JOHNSON	-4.77%	359B
MERCK & CO., INC.	+16.97%	323B
ABBVIE INC.	+5.69%	290B
ASTRAZENECA PLC	+13.68%	234B
NOVARTIS AG	+3.65%	198B
ROCHE HOLDING AG	-11.12%	194B
PFIZER, INC.	-3.40%	157B

Other Pharmaceuticals